Guggenheim Upgrades Avalyn Pharma (NASDAQ:AVLN) to “Strong-Buy”

Avalyn Pharma (NASDAQ:AVLN) was upgraded by research analysts at Guggenheim to a “strong-buy” rating in a note issued to investors on Monday,Zacks.com reports.

A number of other analysts have also recently weighed in on AVLN. Jefferies Financial Group started coverage on shares of Avalyn Pharma in a report on Monday. They issued a “buy” rating and a $52.00 price target on the stock. Evercore assumed coverage on shares of Avalyn Pharma in a research note on Tuesday. They issued an “outperform” rating and a $51.00 target price for the company. Morgan Stanley assumed coverage on shares of Avalyn Pharma in a research note on Tuesday. They issued an “overweight” rating and a $53.00 target price for the company. Finally, Wall Street Zen upgraded shares of Avalyn Pharma to a “hold” rating in a research note on Saturday, May 9th. Two equities research analysts have rated the stock with a Strong Buy rating and two have given a Buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Strong Buy” and a consensus price target of $59.00.

Avalyn Pharma Price Performance

NASDAQ:AVLN opened at $26.70 on Monday. Avalyn Pharma has a fifty-two week low of $25.05 and a fifty-two week high of $32.22.

Insider Buying and Selling

In related news, major shareholder Sr One Capital Management, Llc bought 555,555 shares of the stock in a transaction that occurred on Friday, May 1st. The stock was bought at an average cost of $18.00 per share, for a total transaction of $9,999,990.00. Following the purchase, the insider directly owned 2,186,562 shares of the company’s stock, valued at approximately $39,358,116. This trade represents a 34.06% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Jill Carroll bought 277,778 shares of the stock in a transaction that occurred on Friday, May 1st. The stock was bought at an average price of $18.00 per share, with a total value of $5,000,004.00. Following the completion of the purchase, the director directly owned 2,186,562 shares in the company, valued at $39,358,116. This represents a 14.55% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure.

About Avalyn Pharma

We are a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases with significant unmet needs. Our approach is designed to address the limitations of current oral therapies by delivering optimized inhaled formulations of approved oral medicines directly to the lungs to enhance efficacy and minimize systemic exposure that contributes to side effects and treatment discontinuation. Our current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer.